Though the coronavirus pandemic initially depressed sales, with lab closures early in 2020 and uncertainty on academic research funding, Bio-Techne has also seen some upside. The firm offers direct-to ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company, based in a 9,000 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results